Insider Selling: Amneal Pharmaceuticals (NASDAQ:AMRX) Director Sells $450,557.86 in Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Director Deborah Autor sold 34,819 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the sale, the director directly owned 93,660 shares of the company’s stock, valued at $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Amneal Pharmaceuticals Trading Down 1.3%

Shares of AMRX opened at $12.23 on Friday. The firm has a market capitalization of $3.85 billion, a P/E ratio of 32.19 and a beta of 1.32. Amneal Pharmaceuticals, Inc. has a 12-month low of $7.02 and a 12-month high of $15.42. The firm has a fifty day moving average price of $12.68 and a 200-day moving average price of $12.81.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The firm had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a net margin of 4.01% and a negative return on equity of 313.96%. Analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Analysts Set New Price Targets

AMRX has been the subject of a number of recent analyst reports. Truist Financial boosted their target price on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. Finally, UBS Group initiated coverage on shares of Amneal Pharmaceuticals in a research note on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective for the company. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Institutional Trading of Amneal Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in AMRX. Kemnay Advisory Services Inc. bought a new position in Amneal Pharmaceuticals in the fourth quarter worth about $26,000. Federated Hermes Inc. raised its holdings in Amneal Pharmaceuticals by 1,680.6% in the fourth quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares in the last quarter. Comerica Bank raised its holdings in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares in the last quarter. Spire Wealth Management raised its holdings in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC raised its holdings in Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares in the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.